Benitec Biopharma Files 8-K: Material Agreement & Equity Sales

TL;DR

Benitec Biopharma signed a big deal and sold some stock.

AI Summary

On April 17, 2024, Benitec Biopharma Inc. entered into a Material Definitive Agreement, the details of which are not fully disclosed in this filing. The company also reported on unregistered sales of equity securities and provided a Regulation FD disclosure. The filing includes financial statements and exhibits.

Why It Matters

This 8-K filing indicates significant corporate activity for Benitec Biopharma, including a new material agreement and equity transactions, which could impact its financial position and future operations.

Risk Assessment

Risk Level: medium — The filing mentions a material definitive agreement and unregistered equity sales, which can introduce financial and operational risks.

Key Numbers

• 001-39267 — Commission File Number (Identifies the company's SEC filing history.)
• 2834 — SIC Code (Indicates the company operates in the Pharmaceutical Preparations industry.)

Key Players & Entities

• Benitec Biopharma Inc. (company) — Registrant
• April 17, 2024 (date) — Date of earliest event reported
• 001-39267 (company) — Commission File Number
• 3940 Trust Way, Hayward, California 94545 (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.0001 B — ich registered Common Stock, par value $0.0001 BNTC The Nasdaq Stock Market LLC Indic
• $0.0001 — f the Company's common stock, par value $0.0001 per share (the "Common Stock"), at a pu
• $4.80 — "Common Stock"), at a purchase price of $4.80 per share and (ii) in lieu of shares of
• $4.7999 — Warrant Shares") at a purchase price of $4.7999 per Pre-Funded Warrant (representing th
• $40.0 m — the Private Placement of approximately $40.0 million, before deducting estimated offer

Filing Documents

• d826712d8k.htm (8-K) — 48KB
• d826712dex41.htm (EX-4.1) — 81KB
• d826712dex101.htm (EX-10.1) — 242KB
• d826712dex102.htm (EX-10.2) — 78KB
• d826712dex103.htm (EX-10.3) — 18KB
• d826712dex104.htm (EX-10.4) — 14KB
• d826712dex991.htm (EX-99.1) — 12KB
• 0001193125-24-101289.txt ( ) — 738KB
• bntc-20240417.xsd (EX-101.SCH) — 3KB
• bntc-20240417_lab.xml (EX-101.LAB) — 17KB
• bntc-20240417_pre.xml (EX-101.PRE) — 11KB
• d826712d8k_htm.xml (XML) — 3KB

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," or the negative of these terms, and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to, any statements relating to the Private Placement, anticipated proceeds from the Private Placement and the use thereof, the Company's plans to file a registration statement to register the resale of the shares of Common Stock (including those issuable upon exercise of the Pre-Funded Warrants), the Company's pipeline of ddRNAi-based therapeutics, including the progress and outcomes of clinical trials and any other statements that are not historical facts. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including risks relating to the Company's inability, or the inability of the Purchasers, to satisfy the conditions to closing for the Private Placement and risks relating to the closing of the Private Placement. Other risks and uncertainties include, but are not limited to, risks and uncertainties relating to the difficulties or delays in the Company's plans to develop and potentially commercialize its product candidates, the timing of completion of pre-clinical studies and clinical trials, the timing of the availability of data from our clinical trials, the timing and sufficiency of patient enrollment and dosing in clinical trials, the timing and outcome of expected regulatory filings and approvals, the clinical utility and potential attributes and benefits of ddRNAi and the C

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 4.1 Form of Pre-Funded Warrant 10.1* Securities Purchase Agreement, dated April 17, 2024, by and among Benitec Biopharma Inc. and each purchaser identified on the signature pages thereto 10.2 Form of Registration Rights Agreement 10.3 Form of Voting Commitment Agreement 10.4 Form of Board Designation Agreement 99.1 Press Release, dated April 18, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BENITEC BIOPHARMA INC. Date: April 18, 2024 /s/ Jerel A. Banks Name: Jerel A. Banks Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR